Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC (PRTC)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
10/31 Pfizer expects broad interest for consumer health business
10/31DJSANOFI : and Regeneron Report Positive Asthma Trial Results
10/27DJMARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
10/27DJMARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
10/27DJMARKET SNAPSHOT : S&P 500, Nasdaq Climb After Stronger-than-expected GDP, Hot Te..
10/26DJGILEAD SCIENCES : Looks Away From Hepatitis C Treatments for Growth
10/26 GlaxoSmithKline's new boss struggles to sell cure for drugmaker
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/28 Lonza CFO sees in-house growth, not takeovers, to grow drug services
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
08/28 Gilead to buy Kite for promising cancer therapies in $12 billion deal
08/28DJGILEAD SCIENCES : The Promising New Cancer Treatment Behind Gilead's $11 Billion..
08/28DJHot Stocks to Watch in the U.S. and Canada
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- Update
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion in Cash
08/24 Cyclicals boost European shares while Dixons Carphone plummets
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
07/27DJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/19 Poor test results for Roche cloud growth prospects
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
07/05 Threat to HIV business spooks GlaxoSmithKline shares
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/14 Sanofi to invest further in biologics
06/02DJBluebird Bio stock jumps 7% after Maxim Group upgrades to buy -- MarketWatch
05/31 GILEAD SCIENCES : and GSK go head-to-head with similar HIV drug data
Financials ($)
Sales 2017 1,63 M
EBIT 2017 -120 M
Net income 2017 -97,2 M
Finance 2017 171 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 134x
EV / Sales 2018 97,8x
Capitalization 388 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
PURETECH HEALTH PLC5.09%388
CELLTRION, INC.--.--%25 050
IQVIA HOLDINGS INC37.36%22 053
INCYTE CORPORATION5.19%20 882
LONZA GROUP59.15%19 928
ALNYLAM PHARMACEUTICALS, INC.240.57%12 981
SEATTLE GENETICS, INC.13.30%8 499
NEKTAR THERAPEUTICS266.67%7 870
ALKERMES PLC-12.92%7 590
QIAGEN NV6.61%7 414
EXACT SCIENCES CORPORATION340.64%7 153
IONIS PHARMACEUTICALS INC13.21%6 780
ICON PLC55.92%6 347
UNITED THERAPEUTICS CORPORATION-14.23%5 419
PRA HEALTH SCIENCES INC46.41%5 296
BIO-TECHNE CORP25.66%4 950
CHARLES RIVER LABORATORIES INTL. INC33.08%4 851
GALAPAGOS26.90%4 740
PUMA BIOTECHNOLOGY INC243.65%3 937
FIBROGEN INC119.04%3 920
INC RESEARCH HOLDINGS INC-28.23%3 892